diabetes

MannKind rewarded for positive Afrezza data with $40M financing
Fierce Biotech
Fri, 08/16/13 - 10:47 am
MannKind
Afrezza
diabetes
inhaled insulin
U.S. Insulin Prices Rise as Sanofi, Novo Await Rivals
Bloomberg
Fri, 08/16/13 - 10:42 am
insulin
diabetes
Sanofi
Novo Nordisk
Levemir
Lantus
Victoza
Pfizer, Sanford-Burnham Team Up on Obesity, Diabetes Target Research
GenEngNews
Wed, 08/14/13 - 10:23 am
Pfizer
Sanford-Burnham Medical Research Institute
R&D
obesity
diabetes
Osiris shares rocket, company details Grafix study
Yahoo/AP
Tue, 08/13/13 - 04:09 pm
Grafix
Osiris Therapeutics
diabetes
diabetic foot ulcers
Avanir Pharma to co-promote Merck's diabetes drugs; shares rise
Reuters
Tue, 08/13/13 - 10:42 am
Avanir
Merck
diabetes
Januvia
Janumet
Janumet XR
Novo Nordisk Getting Its Trial By Fire
Investopedia
Fri, 08/9/13 - 09:44 am
earnings
Novo Nordisk
diabetes
Teva
Eli Lilly
Sanofi
Oramed Expands Diabetes Platform With Oral GLP-1 Agonist
Seeking Alpha
Tue, 08/6/13 - 10:00 am
GLP-1 agonist
diabetes
Oramed
Biodel
Bristol-Myers Squibb
Eli Lilly
MannKind
Novo Nordisk
Merck
Afrezza
Januvia
Victoza
MannKind, Vical, GTx: Investors Predict Pivotal Clinical Trial Results
TheStreet.com
Mon, 08/5/13 - 07:23 am
MannKind
Vical
clinical trials
GTx
diabetes
Afrezza
melanoma
Allovectin-7
enobosarm
lung cancer-related muscle wasting
GlaxoSmithKline diabetes drug faces U.S. approval delay
Reuters
Sat, 08/3/13 - 10:11 am
albiglutide
type 2 diabetes
diabetes
GlaxoSmithKline diabetes drug faces U.S. approval delay
Reuters
Fri, 08/2/13 - 10:54 am
GSK
diabetes
albiglutide
FDA
Are These Diabetes Drugs Safe After All?
Motley Fool
Thu, 08/1/13 - 09:17 am
Januvia
Merck
Byetta
Bristol-Myers Squibb
diabetes
type 2 diabetes
Lexicon Pharma's Never-Ending Diabetes Drug Partner Talks
The Street
Thu, 08/1/13 - 09:14 am
Lexicon Pharmaceuticals
LX4211
type 2 diabetes
diabetes
Rhythm Pharmaceuticals lands $11M tranche to advance its treatment of GI disorders
bizjournals
Wed, 07/31/13 - 10:05 am
Rhythm Pharmaceuticals
gastroparesis
diabetes
obesity
Why Biodel Will Have Positive Phase II Results
Seeking Alpha
Wed, 07/31/13 - 09:20 am
Biodel
BIOD-123
type 1 diabetes
type 2 diabetes
diabetes
First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes
Yahoo/PR Newswire
Wed, 07/31/13 - 09:11 am
Tradjenta
diabetes
type 2 diabetes
Boehringer Ingelheim
Eli Lilly
2 Keys to Success for This Diabetes Drug's Second Chance
Motley Fool
Tue, 07/30/13 - 11:35 am
diabetes
AstraZeneca
Bristol-Myers Squibb
Forxiga
Diabetes Drugs’ Pancreas Risk Not Backed by Evidence: EMA
Bloomberg
Fri, 07/26/13 - 09:03 am
diabetes
Europe
Byetta
Bristol-Myers Squibb
Merck
Januvia
GLP-1 agonist
Novo Nordisk
Victoza
AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin
Fierce Biotech
Thu, 07/25/13 - 11:16 am
diabetes
Dapagliflozin
Bristol-Myers Squibb
AstraZeneca
Novo Nordisk: A Pure Play In The Large And Lucrative Diabetes Care Sector
Seeking Alpha
Tue, 07/23/13 - 11:14 am
Novo Nordisk
diabetes
MannKind
Merck
The Diabetes Pipeline With a Clog
Motley Fool
Mon, 07/22/13 - 06:02 pm
diabetes
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
JNJ
SGLT2 inhibitor
Forxiga
Invokana
empagliflozin

Pages